Kymer­a's top drug hunter leaves for Alex­is Borisy's Curie.Bio; What’s done is Dunn: FDA neu­ro­science leader bows out

By day two of his job as CSO part­ner at Alex­is Borisy’s new in­vest­ment and biotech ser­vices firm, Chris De Savi had al­ready gone through the due dili­gence with mul­ti­ple founders look­ing to get their ideas off the ground and in­to the ex­per­i­men­ta­tion phase.

The for­mer Kymera Ther­a­peu­tics drug dis­cov­ery leader joined Curie.Bio this week to prop up new biotech founders and pro­vide ex­per­tise to get their sci­ence and tech up to snuff. He’s the first of what will like­ly be about half a dozen CSO part­ners to be hired at Curie this year as the com­pa­ny looks to build out a 50- to 60-per­son team that helps ear­ly-stage en­tre­pre­neurs turn their ideas in­to 12- to 24-month ex­per­i­men­tal plans that can get them to da­ta that will woo Se­ries A in­vestors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.